Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone

Journal of Clinical Psychopharmacology

Volumn 17, Issue 2, 1997, Pages 113-117

  Eap, Chin B ^a   Bertschy, Gilles ^a   Powell, Kerry ^a   Baumann, Pierre ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; METHADONE;

ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; HUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; STEREOCHEMISTRY;

FLUOXETINE; FLUVOXAMINE; HUMANS; METHADONE; NARCOTICS; SEROTONIN UPTAKE INHIBITORS; STATISTICS, NONPARAMETRIC; STEREOISOMERISM; SUBSTANCE-RELATED DISORDERS;

EID: 0030890624     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199704000-00010     Document Type: Article

References (39)

1. Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry 1986;43:733-8.
2. Maremmani I, Castrogiovanni P, Daini L, Zolesi O. Use of fluoxetine in heroin addiction. Br J Psychiatry 1992;160:570-1.
3. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-5.
4. Bertschy G, Eap CB, Powell K, Baumann P. Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. Ther Drug Monit 1996;18:570-2.
5. Batki SL, Manfredi LB, Jacob P III, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol 1995;13:243-50.
6. Kristensen K, Christensen CB, Christrup LL. The mu(1), mu(2), delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1994;56:45-50.
7. Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, Baumann P. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addict patients. Interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 1996;50:385-9.
8. Eap CB, Gaillard N, Powell K, Baumann P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1996;682:265-72.
9. Baumann P. Clinical pharmacokinetics of citalopram and other selective serotoninergic reuptake inhibitors (SSRI). Int Clin Psychopharmacol 1992;6[suppl 5]:13-20.
10. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction - an accidental finding. Eur J Clin Pharmacol 1991;40:119-20.
11. Härtter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 1993;110:302-8.
12. Beck O, Boreus LO, Lafolie P, Jacobsson G. Chiral analysis of methadone in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1991;570:198-202.
13. Schmidt N, Brune K, Geisslinger G. Stereoselective determination of the enantiomers of methadone in plasma using high-performance liquid chromatography. J Chromatogr B Biomed Appl 1992;583:195-200.
14. Kristensen K, Angelo HR. Stereospecific gas chromatographic method for determination of methadone in serum. Chirality 1992; 4:263-7.
15. Sullivan HR, Due SL. Urinary metabolites of d-methadone in maintenance subjects. J Med Chem 1973;16:909-13.
16. Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-7.
17. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
18. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
19. Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone. Am J Psychiatry 1990;147:1379-80.
20. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
21. Mikus G, Somogyi AA, Bochner F, Eichelbaum M. Codeine O-demethylation: rat strain differences and the effects of inhibitors. Biochem Pharmacol 1991;41:757-62.
22. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993;35:30-4.
23. Änggard E, Gunne L-M, Holmstrand J, McMahon RE, Sandberg CG, Sullivan HR. Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 1975;17:258-66.
24. Yue Q-Y, Svensson J-O, Bertilsson L, Säwe J. Racemic methadone kinetics in relation to the debrisoquine hydroxylation polymorphism in man [abstract]. Abstracts of the 1st Congress of the European Association for Clinical Pharmacology and Therapeutics, September 27-30, 1995. Therapie 1995;[suppl]:88.
25. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
26. Borg L, Kreek MJ. Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-1-positive and AIDS patients. Curr Opin Psychiatry 1995;8:199-202.
27. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990;45:241-98.
28. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase in human liver microsomes. Br J Clin Pharmacol 1995;40:481-5.
29. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, François T, Sechter D, Bizouard P. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-53.
30. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994;9[suppl 3]:13-9.
31. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of paroxetine and other specific 5-HT re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol 1991;32:658P-659P.
32. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 1995;9:163-78.
33. Rasmussen BB, Mäenpäa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
34. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Pharmacol 1995;15:125-32.
35. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
36. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjøqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population - analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-20.
37. Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57: 265-9.
38. Nilsson M-I, Grönbladh L, Widerlöv E, Änggard E. Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures. Eur J Clin Pharmacol 1983; 25:497-501.
39. Tennant FS Jr. Inadequate plasma concentrations in some high-dose methadone maintenance patients. Am J Psychiatry 1987; 144:1349-50.